Keros Therapeutics (NASDAQ:KROS) Shares Gap Down to $44.58

Keros Therapeutics, Inc. (NASDAQ:KROS) shares gapped down before the market opened on Tuesday . The stock had previously closed at $44.58, but opened at $43.57. Keros Therapeutics shares last traded at $43.89, with a volume of 6,401 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently commented on the company. William Blair restated an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Wedbush restated an “outperform” rating and issued a $86.00 target price on shares of Keros Therapeutics in a report on Thursday, February 29th. Piper Sandler restated an “overweight” rating and issued a $105.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday. Finally, Truist Financial reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $86.00.

Keros Therapeutics Trading Down 0.4 %

The firm’s 50-day simple moving average is $53.73 and its 200 day simple moving average is $53.75. The stock has a market cap of $1.60 billion, a P/E ratio of -8.66 and a beta of 1.25.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.12. The business had revenue of $0.08 million during the quarter. During the same period last year, the company earned ($1.26) earnings per share. The company’s revenue for the quarter was down 97.3% compared to the same quarter last year. On average, analysts anticipate that Keros Therapeutics, Inc. will post -4.97 EPS for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Keros Therapeutics by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after acquiring an additional 113,563 shares during the last quarter. Darwin Global Management Ltd. increased its holdings in Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after buying an additional 375,523 shares during the last quarter. Braidwell LP increased its position in Keros Therapeutics by 18.7% in the third quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock worth $43,271,000 after buying an additional 213,444 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Keros Therapeutics by 47.9% in the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock valued at $27,809,000 after purchasing an additional 226,674 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.